A retrospective real-world study strengthens evidence that early, sustained treatment with the antiamyloid lecanemab can slow ...
Preliminary clinical evidence of Lisaftoclax overcoming venetoclax resistance in myeloid malignancies with a 31.8% overall ...
Lisaftoclax monotherapy demonstrated significant and durable clinical efficacy and a manageable safety profile in patients ...
NEW YORK--(BUSINESS WIRE)--Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, today announced the launch of Medidata Clinical Data ...
The pharmaceutical and medical device industries stand at an inflection point. After decades of reliance on traditional ...
Study data suggests IGV-001 provides patients with a clinically meaningful improvement in overall survival (+6.3 months; +45%) compared to the current standard of care for ndGBM –– Company plans to ...
Patients enrolled on the Children's Oncology Group neuroblastoma biology study ANBL00B1 (ClinicalTrials.gov identifier: NCT00904241) who received care at the University of Chicago (UChicago) or the ...
Phase 1 Study in Non-Small Cell Lung Cancer Combined Reqorsa® Gene Therapy with Tagrisso® AUSTIN, Texas, Nov. 24, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or ...
GLP-tox study reinforces favorable safety profile of Tiprelestat Phase II Study in Pulmonary Arterial Hypertension (PAH) to ...
LAGUNA BEACH, Calif., Dec. 2, 2025 /PRNewswire/ -- Ryght AI, the leading intelligent platform for clinical trial site selection, feasibility, and study operations today announced it will host a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback